Suggestions on how long it will take before the effect of Lynparza is seen after taking it

Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, mainly used to treat ovarian cancer, breast cancer, prostate cancer and pancreatic cancer related to BRCA mutations. Generally speaking, after oral administration of olaparib, the drug will reach its peak blood level within 1 to 2 hours, but clinical efficacy often takes longer to manifest. Most patients can only observe obvious therapeutic effects through imaging or tumor marker changes after continuous treatment for 4 to 8 weeks.由于个体代谢能力、肿瘤类型、突变状态及既往治疗史不同，起效时间可能存在明显差异。

If the patient still does not feel significant improvement or symptom relief after taking the medicine for 2 to 4 weeks, he should not stop taking the medicine or change the dosage immediately. Efficacy evaluation should be conducted under the guidance of a doctor, including review of tumor markers (such as CA125, PSA, etc.), imaging examinations (CT or MRI) and tolerability analysis. Some patients may experience a "stable disease" stage in the early stage, that is, the tumor does not continue to progress but has not yet shrunk. This is a common early response pattern to Lynparza and still requires continued observation.

If no significant effect is seen after a standard treatment cycle of 8 to 12 weeks, doctors usually consider whether there is a resistance mechanism or insufficient drug exposure. At this time, the patient's gene mutation status (such as BRCA1/2, HRD status), drug interactions, and medication compliance should be assessed. If resistance is confirmed, you can consider changing to other PARP inhibitors (such as niraparib, rucaparib) or combining chemotherapy, immunotherapy and other regimens to improve the efficacy.

在整个治疗过程中，患者应严格遵循医嘱按时服药，避免擅自停药或调整剂量。同时注意监测不良反应，如贫血、恶心、疲劳等，必要时调整用药方案。建议每4至6周进行一次系统评估，以确保疗效与安全性兼顾。 Generally speaking, the evaluation of the efficacy of olaparib should be based on the medium and long-term treatment courses. The lack of obvious short-term effects does not mean that the treatment has failed. The key lies in scientific monitoring and individualized management.

Reference materials:https://www.drugs.com/